Compare Payoneer Global Inc (PAYO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.2× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PAYO | XBI | |
|---|---|---|
Market Cap | $2.43B | $10.11B |
Volume | 1,342,701 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $7.18 | $169.55 |
52-Week Low | $4.27 | $104.99 |
Typical Hold Time | 61 Days | 38 Days |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, down 0.28% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but maintains strong revenue growth and a 78% gross margin. Recent news highlights the renewal of its partnership with Etsy through 2029 and ongoing acquisition discussions with Nuvei.
The stock presents a mixed outlook: analyst consensus is 60% buy with no sell ratings, but elevated P/E of 51.18 and recent earnings misses pose valuation and execution risks. The pending acquisition adds uncertainty, while expansion into India offers growth potential. Investors should weigh strong fundamentals against high expectations and integration challenges.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
